Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Mirati

3 Growth Pharma Stocks to Guard Your Portfolio

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

StockNews.com

Amgen Stock Surges To 10-Month High, Up 5% On An Unexpected Upgrade

Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.

Investors Business Daily

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Price

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Mirati Rockets 33% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit

A treatment regimen from Mirati handily beat Merck's blockbuster Keytruda in some lung cancer patients, and MRTX stock rocketed Wednesday.

Investors Business Daily

Billionaire whose family trust owns Spurs denies insider trading – reports

Joe Lewis, 86, pleaded not guilty to 16 counts of securities fraud and three charges of conspiracy when he appeared at Manhattan District Court.

The Independent UK

What is Tottenham Hotspur billionaire Joe Lewis accused of?

Joe Lewis has been accused of 16 counts of securities fraud in the US. We examine the allegations through the companies he invested in

The Guardian - UK

Tottenham owner Joe Lewis to appear in court on insider trading charges

The 86-year-old has been charged with 16 counts of securities fraud and three counts of conspiracy.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Tottenham Hotspur owner Joe Lewis charged with ‘brazen’ insider trading

Billionaire allegedly gave friends, employees and romantic partners information on companies in which he was investor

The Guardian - US

U.S. FDA approves Mirati's lung cancer drug

The U.S. Food and Drug Administration approved Mirati Therapeutics Inc's lung cancer drug adagrasib, the company said on Monday, sending its shares up more than 8% in extended trading.

Reuters

Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days

Mirati Therapeutics' pain continued Thursday amid a series of analyst downgrades after MRTX stock lost about half of its value in three days.

Investors Business Daily

Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up

Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.

Investors Business Daily

Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle

Big Pharma suitors could be looking to buy Mirati Therapeutics, according to reports that sent MRTX stock close to a breakout Wednesday.

Investors Business Daily

Why Amgen's Cancer Drug Results Gave This Small Cap A Big Boost

Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival Mirati along for the ride.

Investors Business Daily

The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed

Shares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising — test results for a lung cancer treatment.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash

Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.

Benzinga

Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.